# Endostar First-line Treatment of Advanced NSCLC

> **NCT03123445** · PHASE2 · UNKNOWN · sponsor: **China Medical University, China** · enrollment: 150 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Endostar
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03123445
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04
- **Primary completion:** 2019-04
- **Final completion:** 2019-09
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2017-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123445, "Endostar First-line Treatment of Advanced NSCLC". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03123445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*